Oral Thrush (Oropharyngeal Candidiasis)
Clinical Snapshot
Oral thrush — oropharyngeal candidiasis — is overgrowth of Candida species, most often Candida albicans, on the oral and oropharyngeal mucosa. C. albicans is not an invader: it is a normal commensal organism, colonizing the mouths of an estimated 30-60% of healthy adults (and 45-65% of infants) without causing any disease at all.[1] Thrush develops only when something disrupts the local or systemic host defenses that normally keep this colonization in check — a disrupted balance, not a new exposure, which is why the genuinely useful clinical question with oral thrush is almost always "what changed?" rather than "where did this come from?"
The disruption can be purely local — an inhaled corticosteroid depositing in the oropharynx with every dose, a denture creating a warm, low-oxygen, plaque-retentive space against the palate, or reduced salivary flow removing much of saliva's own antimicrobial protection — or it can be systemic: uncontrolled diabetes, a course of broad-spectrum antibiotics disrupting the mouth's normal bacterial flora, or an immunocompromising condition. This distinction, developed fully in Risk Factors, is the organizing idea of this whole chapter: local causes are common and usually straightforward to identify, and the fix is often as much about counseling and technique as it is about an antifungal prescription; a systemic cause — especially one with no obvious explanation — is what turns a routine thrush presentation into a genuine diagnostic opportunity.[2]
Oral thrush is common. It affects otherwise healthy newborns and infants as a benign, self-limited presentation; denture stomatitis specifically is reported in up to 65% of denture wearers; and more than 90% of people with HIV/AIDS develop oral candidiasis at some point in the course of their disease, making it one of the most characteristic opportunistic infections of advanced immunosuppression.[3][1] For most patients seen in a community pharmacy, though, oral thrush is a mild, self-limited, and highly treatable condition — reflecting a recent antibiotic course, an inhaled corticosteroid, or a denture problem — that resolves reliably with an appropriately chosen topical antifungal and a genuine effort to address whatever allowed it to develop in the first place.
The two highest-value things a pharmacist can do for this condition sit at opposite ends of the encounter: prevent it before it starts, in every patient starting or already using an inhaled corticosteroid, with a genuine rinse-and-spit and spacer-technique conversation (see Non-Pharmacologic Management); and recognize when it shouldn't be there at all — persistent or recurrent thrush in a patient with no antibiotic, denture, or inhaled-steroid explanation is a real, actionable signal to raise HIV testing or another immunocompromise workup with the prescriber (see Red Flags and Referral).
Recognize the Condition
The classic pattern — pseudomembranous candidiasis
The presentation most people mean by "oral thrush" is pseudomembranous candidiasis: creamy-white, slightly raised plaques or curd-like patches on the tongue, buccal mucosa, palate, or oropharynx.[2] The single most useful bedside maneuver in this whole chapter is also the simplest: gently wipe a plaque with gauze or a tongue depressor. A pseudomembranous plaque wipes away, exposing a raw, erythematous, sometimes mildly bleeding mucosal surface underneath — the pseudomembrane itself is made up of desquamated epithelial cells, fibrin, and fungal hyphae, not tissue permanently incorporated into the mucosa.[1] Symptoms are often mild or absent; when present, patients describe a cottony feeling, altered or metallic taste, mild burning, or occasionally pain with eating.[2]
Erythematous (atrophic) candidiasis — the pattern that is easy to miss
Erythematous candidiasis presents as diffuse, well-defined red or atrophic patches — commonly on the palate, buccal mucosa, or the dorsum of the tongue, where atrophy of the tongue's filiform papillae can leave a smooth, reddened surface — without the visible white plaques that make pseudomembranous disease easy to spot.[2][1] It frequently follows a course of broad-spectrum antibiotics, which eliminate the competing bacterial flora that normally restrains Candida, or reflects the same corticosteroid, HIV, or nutrient-deficiency causes that produce the pseudomembranous pattern.[1] Patients typically report a burning sensation rather than visible white patches — exactly why this pattern is under-recognized relative to how common it actually is. A sore, red mouth with no obvious white plaque deserves the same "what changed" risk-factor screen as classic thrush.
Hyperplastic candidiasis — the pattern that changes the plan
Hyperplastic candidiasis presents as white plaques that, unlike the pseudomembranous pattern, cannot be wiped off — typically on the buccal mucosa, sometimes extending to the oral commissures, and strongly associated with smoking.[2][1] This is not simply a more stubborn version of ordinary thrush: hyperplastic candidiasis carries a genuine risk of evolving into dysplasia or malignancy, and Candida-associated leukoplakia specifically carries a higher malignant-transformation risk than leukoplakia without candidal involvement.[1] A white plaque that does not wipe off changes the entire plan — see Red Flags and Referral — because it needs biopsy and dental/oral-medicine referral, and treating it as routine thrush risks missing a premalignant or malignant process.
Denture stomatitis — the pattern specific to denture wearers
Denture stomatitis (chronic atrophic candidiasis) is diffuse erythema confined to the denture-bearing mucosa, typically the palate under an upper denture, and is reported in up to 65% of denture wearers.[1] It is often entirely asymptomatic, discovered only when a denture is removed for inspection, though some patients report soreness or burning. Three clinical grades are described: localized pinpoint (petechial) hemorrhage and inflammation (Type I); more diffuse erythema across the denture-bearing area (Type II); and erythema with papillary hyperplasia of the central hard palate (Type III), the most severe pattern.[1] Angular cheilitis (below) frequently accompanies denture stomatitis, and the two are often addressed together.[1]
Angular cheilitis and median rhomboid glossitis — related presentations worth recognizing on sight
Angular cheilitis is erythematous, fissured, sometimes crusted skin at one or both corners of the mouth, driven by a moist, saliva-pooled environment — commonly from lip overclosure around a poorly supported denture — that favours both Candida and, frequently, a co-existing bacterial component (Staphylococcus aureus or streptococcal species).[1] It is also linked to iron, folate, B12, and riboflavin deficiency, worth asking about in a recurrent or refractory case.[1] Median rhomboid glossitis is an uncommon (well under 1% of the population) well-defined, rhomboid-shaped erythematous patch on the midline dorsum of the tongue, just anterior to the circumvallate papillae, from localized atrophy of the filiform papillae; it is associated with smoking and inhaled steroid use, and a matching ("kissing") lesion on the opposing palate is a recognized marker that should prompt consideration of underlying immunosuppression, including HIV (see Red Flags and Referral).[1]
| Presentation | Wipes off? | Typical location | Classic association |
|---|---|---|---|
| Pseudomembranous ("classic" thrush) | Yes — leaves raw, erythematous mucosa | Tongue, buccal mucosa, palate, oropharynx | Recent antibiotics, corticosteroids (inhaled or systemic), dry mouth, immunocompromise |
| Erythematous (atrophic) | No visible plaque — diffuse redness instead | Palate, buccal mucosa, tongue dorsum | Antibiotics, corticosteroids, HIV, iron/B12 deficiency |
| Hyperplastic | No — persistent white plaques | Buccal mucosa, oral commissures | Smoking; carries dysplasia/malignancy risk — biopsy, not routine treatment |
| Denture stomatitis (chronic atrophic) | N/A — erythema, not a plaque | Denture-bearing palate | Poor denture hygiene/fit, continuous (24-hour) wear |
| Angular cheilitis | N/A — fissuring, not a plaque | Corners of the mouth | Denture-related lip overclosure, nutrient deficiency |
Risk Factors
Local disruption of host defense
- Inhaled corticosteroids — the genuinely pharmacist-relevant risk factor at the centre of this chapter. Every dose from an inhaled corticosteroid, regardless of device (metered-dose inhaler, dry powder inhaler, or soft mist inhaler), deposits a portion of the drug in the oropharynx rather than the lower airway; that locally deposited steroid produces local immunosuppression of the oral mucosa, permitting Candida overgrowth. The Canadian Pharmacists Association lists corticosteroids, "e.g., asthma inhalers," directly among the medical causes of thrush, and the Journal of the Canadian Dental Association's guidance for managing oral candidiasis specifically instructs inhaler users to brush or rinse the palate after each use and to have their technique reviewed.[3][2] Asthma Canada is explicit about both the mechanism and the fix: "sore throat and thrush are commonly caused by poor puffer technique," and rinsing the mouth after every dose "will also help reduce these side effects."[4] See Non-Pharmacologic Management for the complete, step-by-step version of this counseling — it is the single highest-value prevention conversation in this chapter.
- Dentures — a denture, especially one worn continuously (including overnight), poorly cleaned, or poorly fitting, creates a warm, low-oxygen, plaque-retentive microenvironment against the palate that favours Candida overgrowth; denture stomatitis specifically is reported in up to 65% of denture wearers.[1][2]
- Broad-spectrum antibiotics — by suppressing the competing bacterial oral flora that normally restrains Candida, leaving it to overgrow unchecked; this is one of the most common precipitants of a short, self-limited episode.[2][3]
- Xerostomia (dry mouth) — saliva carries antifungal and antibacterial proteins and provides mechanical clearance; reduced salivary flow, whether from medication, Sjögren syndrome, radiation, or dehydration, removes much of this protection (see this platform's Dry Mouth chapter for the full medication-review approach to xerostomia itself).[3]
- Topical corticosteroid use elsewhere in the mouth — a topical corticosteroid gel or paste used for oral lichen planus or aphthous ulcers can produce the same local effect as an inhaled corticosteroid.[2]
Systemic disruption of host defense
- Diabetes mellitus, particularly poorly controlled — elevated salivary and mucosal glucose provides a direct nutrient source for Candida, and hyperglycemia itself impairs neutrophil function.[2][3]
- HIV/AIDS and other immunocompromising conditions — more than 90% of people with HIV/AIDS develop oral candidiasis at some point in the course of their disease, making it one of the most characteristic opportunistic infections of HIV, and a presentation that in an undiagnosed patient can be the first visible sign of the disease (see Red Flags and Referral).[1]
- Systemic corticosteroids, chemotherapy, and organ-transplant antirejection therapy — all produce a more global suppression of cell-mediated immunity than a topical or inhaled corticosteroid alone.[2]
- Malnutrition and specific nutrient deficiency — iron, folate, and vitamin B12 deficiency are recognized contributors, particularly to erythematous candidiasis and angular cheilitis.[1]
- Extremes of age — healthy newborns and infants (an immature immune system, and possible vertical or breastfeeding-related transmission) and frail older adults (a combination of polypharmacy, dentures, and reduced physiologic reserve) are both overrepresented.[3]
- Head and neck radiation therapy — direct mucosal injury plus the radiation-associated xerostomia covered above compound the risk.[2]
Every local risk factor above is genuinely correctable with counseling, denture care, or antifungal treatment alone. The absence of any of them — no recent antibiotic, no inhaled or topical corticosteroid, no denture, well-controlled or absent diabetes — is itself a meaningful finding, not a reassuring one: it is exactly the pattern that should prompt the immunocompromise conversation in Red Flags and Referral.
Red Flags & Refer
Most oral thrush a pharmacist encounters has an obvious local explanation — a recent antibiotic, an inhaled corticosteroid, or a denture — and resolves reliably with an appropriately chosen antifungal and the counseling in this chapter. The findings below change that plan.
- Recurrent or persistent oral thrush with no identifiable local cause — no recent antibiotic course, no inhaled or topical corticosteroid, no denture, and no poorly controlled diabetes — is the single most important red flag in this chapter. More than 90% of people with HIV/AIDS develop oral candidiasis at some point in their disease course, and it is frequently among the earliest visible signs of previously undiagnosed HIV infection.[1] Discuss HIV testing directly with the patient's prescriber, or, where the pharmacist's scope and the patient's comfort allow, raise it directly, rather than simply repeating another course of antifungal treatment.[1]
- A matching ("kissing") lesion on the palate opposite a median rhomboid glossitis patch is specifically described as a potential marker of underlying immunosuppression and warrants the same investigation.[1]
- White plaques that do not wipe off (hyperplastic candidiasis) — not simply a more resistant version of ordinary thrush. It carries a genuine risk of dysplasia or malignant transformation, particularly in smokers, and needs biopsy and dental/oral-medicine referral rather than an extended antifungal trial alone.[1]
- Odynophagia or dysphagia — pain or difficulty swallowing — suggests the infection has extended into the esophagus (candidal esophagitis). This needs prompt medical assessment; an empiric trial of oral fluconazole is a reasonable first step, but persistent symptoms despite treatment warrant referral for endoscopy rather than repeated empiric courses.[5]
- Fever, spreading facial or neck swelling, or signs of systemic illness in a patient who is immunocompromised — raises concern for invasive or disseminated candidiasis, which needs urgent medical assessment rather than pharmacy-level management.
- An unwell-appearing infant — poor feeding, fever, lethargy — with oral thrush needs pediatric assessment; straightforward thrush in an otherwise well, feeding infant does not.
- No improvement despite an adequately dosed, adherent, minimum-2-week course of topical antifungal therapy — reassess the diagnosis (is this actually hyperplastic candidiasis, leukoplakia, or oral lichen planus rather than pseudomembranous thrush?), confirm denture disinfection actually occurred if relevant, and consider stepping up to oral fluconazole rather than simply repeating the same topical course (see Treatment Failure/Next Step).
Assessment & Diagnosis
History
Ask specifically about each of the local and systemic risk factors in Risk Factors: any antibiotic in the past few weeks, current or recent corticosteroid use of any kind (inhaled, topical, or systemic) — and, for inhaled corticosteroid users, actual technique (spacer use, post-dose rinsing) — denture use and hygiene habits, diabetes history and control, smoking, and any known immunocompromising condition or HIV risk factors.[2][1] Ask about symptoms (burning, taste change, pain with eating) and, critically, whether swallowing itself is painful or difficult — this distinguishes oropharyngeal from possible esophageal extension (see Red Flags and Referral).
Examination
Examine the tongue (dorsum and lateral borders), buccal mucosa, hard and soft palate, floor of mouth, and the corners of the mouth; in a denture wearer, examine the denture-bearing mucosa with the denture removed. For any white plaque, gently attempt to wipe it away with gauze or a tongue depressor — this single maneuver is the key bedside differentiator between pseudomembranous disease (wipes off, leaving raw erythematous mucosa) and hyperplastic disease (does not wipe off) described in Recognize the Condition.[1]
Diagnosis is clinical
Diagnosis of oral candidiasis is made clinically, based on the history and examination above.[2][1] Culture or microscopy (potassium hydroxide preparation, exfoliative cytology) is reserved for atypical presentations, treatment failure, or when the diagnosis is genuinely unclear — not for routine, classic presentations.[2][1] Where formal testing is unavailable, a clear clinical response to an appropriate antifungal trial is itself considered supportive, retrospective confirmation of the diagnosis.[2]
Biopsy — reserved for one specific pattern
Biopsy is specifically indicated for chronic hyperplastic candidiasis, given its dysplasia/malignancy risk, and is not part of the routine workup of ordinary pseudomembranous or erythematous disease.[1] Where hyperplastic candidiasis is suspected, a short course of systemic antifungal treatment before biopsy is sometimes used clinically to help distinguish true epithelial dysplasia from Candida-associated changes that may resolve with treatment — a dental/oral-medicine-directed decision, not a pharmacy one.[1]
When to test for an underlying cause
A straightforward case with an obvious local cause and none of the Red Flags and Referral findings does not need laboratory workup. Pursue further testing when those criteria are met: blood glucose/HbA1c if diabetes is suspected but undiagnosed, and HIV testing — plus, where clinically indicated, assessment for adrenal insufficiency, malnutrition, or another cause of immunocompromise — for recurrent or unexplained disease.[1]
A brief differential — what else this could be
| Feature | Pseudomembranous thrush | Oral hairy leukoplakia | Leukoplakia | Oral lichen planus |
|---|---|---|---|---|
| Wipes off? | Yes | No | No | No — a lacy pattern, not a discrete plaque |
| Typical location | Tongue, buccal mucosa, palate | Lateral tongue border, often bilateral, corrugated ("hairy") texture | Anywhere on the oral mucosa | Bilateral buccal mucosa, lacy white (Wickham) striae |
| Cause | Candida overgrowth | Epstein-Barr virus; essentially specific to significant immunosuppression, especially HIV | Idiopathic; premalignant potential | Immune-mediated; not infectious |
| Key next step | Antifungal trial — resolves | Does not resolve with antifungal treatment; itself a marker of significant immunosuppression — HIV testing | Biopsy; smoking cessation | Biopsy if diagnosis unclear; not antifungal-responsive |
Treatment Targets
- Eradicate active infection with an antifungal matched to severity, extent, and the patient's ability to actually use it (for example, adequate saliva to dissolve a troche).
- Identify and address the local or systemic cause — the single highest-value pharmacist action in this chapter, and the only intervention that prevents the next episode rather than just treating this one.
- For every patient using an inhaled corticosteroid, deliver genuine rinse-and-spit and spacer-technique counseling — the model prevention conversation this chapter is built around, deliverable at literally every refill.
- For denture wearers, treat the mucosa and the denture together; an antifungal alone, without denture disinfection, reliably fails.
- Recognize hyperplastic candidiasis (a white plaque that does not wipe off) and route it to biopsy rather than treating it as routine thrush.
- Recognize recurrent or unexplained thrush with no local cause as a genuine prompt to discuss HIV testing or another immunocompromise workup, rather than a reason to simply repeat treatment.
- Set realistic expectations for timeline — improvement within 48-72 hours, a minimum 2-week course continued a few days past symptom resolution — to support adherence and prevent early relapse.
Choose Initial Treatment
Match therapy to severity and extent — and always ask why
Topical antifungal therapy is first-line for mild-to-moderate, localized oropharyngeal disease; oral fluconazole is reserved for moderate-to-severe disease, disease that has not responded to an adequate topical course, or any suggestion of esophageal extension.[2][5] Choosing the right drug is only half the plan — every case also needs the "what changed" risk-factor review from Assessment/Diagnosis, because the antifungal treats this episode and the risk-factor conversation is what actually prevents the next one.
Build the plan in this order
Step 1 — mild-to-moderate, localized disease topical nystatin oral suspension or clotrimazole troches, for a minimum of 2 weeks, continued for several days after symptoms have resolved to reduce the chance of early relapse.[2][3] Choose based on the patient's ability to actually use the product: troches need adequate saliva and roughly 15-20 minutes to dissolve fully and are less suitable for a patient with significant dry mouth; suspension requires a longer swish time but no dissolution.[2]
Step 2 — moderate-to-severe disease, disease not responding to an adequate topical course, or denture stomatitis unresponsive to denture care alone oral fluconazole 100-200 mg once daily for 7-14 days.[5][2]
Step 3 — odynophagia/dysphagia suggesting esophageal extension oral fluconazole 200-400 mg once daily for 14-21 days, and refer for prompt medical assessment; persistent symptoms despite an adequate empiric trial warrant endoscopy rather than a longer empiric course.[5]
Step 4 — fluconazole-refractory disease itraconazole oral solution, posaconazole, or voriconazole — specialist-directed (infectious diseases or oral medicine), not a routine pharmacy-initiated step (see Treatment Failure/Next Step).[5]
Every denture wearer, regardless of step treat the mucosa and disinfect — or, if warranted, refit — the denture together; see Non-Pharmacologic Management. Antifungal treatment without addressing the denture reliably fails.[2]
Every patient on an inhaled corticosteroid, regardless of step treat the active infection, and use the encounter as the opportunity for the rinse-and-spit/spacer-technique conversation in Non-Pharmacologic Management. Do not suggest stopping or reducing the inhaled corticosteroid for thrush — raise technique and prevention, and leave any dose decision to the prescriber managing the patient's asthma or COPD.[3][4]
White plaque that does not wipe off, or any other Red Flags and Referral finding do not proceed with routine antifungal treatment alone — see Red Flags and Referral.
Non-Pharmacologic Treatment
Inhaled corticosteroid technique — the model prevention conversation for this chapter
This is prevention, not treatment of an active infection — but it is the single highest-value thing a pharmacist can do for oral thrush, because it can stop the infection from ever developing in the first place, in a population (asthma and COPD patients on a controller inhaler) that a community pharmacist sees at essentially every refill.
Every dose from an inhaled corticosteroid deposits a portion of the drug in the oropharynx — on the tongue, palate, and back of the throat — rather than reaching the lower airway where it is needed; that locally deposited steroid suppresses local mucosal immunity and allows Candida to overgrow. The Canadian Pharmacists Association lists corticosteroids, "e.g., asthma inhalers," directly among the medical causes of thrush, and the Journal of the Canadian Dental Association's guidance for managing oral candidiasis specifically instructs inhaler users to brush or rinse the palate after each use and to have their technique reviewed.[3][2] Asthma Canada is explicit about the mechanism and the fix: "sore throat and thrush are commonly caused by poor puffer technique... rinsing out your mouth with water after every dose of inhaled corticosteroids will also help reduce these side effects."[4]
Rinse and spit — after every single dose
Counsel every patient starting or already using an inhaled corticosteroid, of any age and with any device, to rinse the mouth with plain water immediately after each dose and to spit the water out rather than swallow it — the goal is to physically clear residual deposited steroid from the oral mucosa before it has a chance to act locally, not simply to freshen breath. This is a genuinely low-effort, zero-cost intervention a patient can start the same day it is raised, and it belongs in the counseling for every new inhaled-corticosteroid prescription and every refill, not just a one-time mention at initiation.[4][3]
Spacer use — for every metered-dose inhaler, at any age
A spacer is a chamber that attaches to a metered-dose inhaler (puffer) so the medication is drawn in through the tube rather than sprayed directly into the mouth; this substantially reduces how much drug is deposited on the tongue, palate, and oropharynx and increases how much actually reaches the lower airway. Asthma Canada states this directly: "if sprayed into your mouth, the medication can cause side effects like thrush," and recommends that "anyone, of any age, who is using a puffer should consider using a spacer."[4] The technique itself is worth walking through explicitly, since correct use is what actually delivers the benefit:
- Shake the puffer well (3-4 shakes) and remove the caps from both the puffer and the spacer.
- Insert the puffer into the spacer.
- Breathe out fully, away from the spacer.
- Bring the spacer to the mouth and seal the lips around the mouthpiece.
- Press the top of the puffer once — only one puff into the spacer at a time.
- Breathe in slowly and fully (a whistling sound means breathing in too fast).
- Hold the breath for about 10 seconds, then breathe out.
- If a second puff is needed, wait at least 30 seconds and shake the puffer again before repeating.
Dry powder inhalers — no spacer, but the rinse still applies
Spacers are specifically for puffer-style (metered-dose or soft mist) inhalers and should not be used with a dry powder inhaler (for example, a Diskus or Turbuhaler) — the dose is drawn into the lungs by the patient's own inspiratory effort, and a spacer would interfere with that.[4] Oropharyngeal deposition and the resulting thrush risk are not unique to metered-dose inhalers, though — the same rinse-and-spit habit after every dose applies regardless of device type.[4][2]
Never stop or reduce an inhaled corticosteroid because of thrush
Treat the active infection with an appropriate antifungal (see Pharmacologic Management), and reinforce technique — do not suggest the patient stop or reduce their inhaled corticosteroid on account of thrush. Inhaled corticosteroids are the most effective controller therapy for asthma, and stopping one because of a treatable side effect risks the patient's underlying respiratory disease for a problem that technique correction and a short antifungal course reliably solve. Any dose change belongs with the prescriber managing the patient's asthma or COPD, not as a pharmacy-initiated response to thrush.[4]
Technique review is not a one-time conversation. Many people do not use their inhalers properly, and every type of inhaler technique should be checked regularly by a healthcare provider — a community pharmacy refill is one of the most natural, repeatable opportunities in the entire healthcare system to ask a patient to demonstrate their technique and correct it on the spot.[4]
Denture care
- Remove dentures every night, for at least 6-8 hours, to give the denture-bearing mucosa a genuine daily recovery period — continuous 24-hour wear is one of the clearest, most correctable drivers of denture stomatitis.[1]
- Clean and disinfect the denture daily, not just rinse it — soak in a chlorhexidine gluconate 0.12% solution, or, for a denture with no metal components, a dilute sodium hypochlorite (household bleach) solution, roughly 1 teaspoon (5 mL) of bleach per 8 oz (240 mL) of water.[2]
- Never combine a nystatin rinse with a chlorhexidine-based denture soak at the same time — the two inactivate each other; separate them in time if both are being used.[1]
- If the denture fits poorly or has not been reassessed in years, arrange a dental refit or reline — a persistently poor mechanical fit is a common, under-recognized reason denture stomatitis keeps recurring despite good hygiene.
- Once the infection has cleared, replace the toothbrush — an old brush can harbour Candida and reintroduce the infection.[3]
General oral hygiene and other measures
- Brush teeth and tongue twice daily, floss at least once daily, and attend regular dental cleanings — twice yearly is the general benchmark.[3]
- Avoid mouthwash with a high alcohol content used over a long period — it can itself contribute to dry mouth, one of the risk factors this chapter covers.[3]
- Address dry mouth directly where present — frequent sips of water, ice chips, or sugar-free lozenges, and a full medication review for a xerogenic drug (see this platform's Dry Mouth chapter).[3]
- Optimize glycemic control in patients with diabetes, as a genuine adjunct to antifungal treatment rather than a separate, unrelated goal.
- Support smoking cessation, particularly relevant to hyperplastic candidiasis and median rhomboid glossitis, both specifically associated with smoking.[1]
- An episode clearly triggered by a short antibiotic course usually needs nothing beyond a topical antifungal if bothersome — it typically resolves once the antibiotic course finishes and the normal oral flora recovers.
Special Populations
Infants
Healthy newborns and infants commonly develop oral thrush, generally a benign, self-limited presentation reflecting an immature immune system rather than any deeper concern.[3] Nystatin oral suspension applied directly to the lesions is first-line, with weight-based dosing per the product monograph.[1] A simple bedside distinguishing test can help separate thrush from milk residue: milk residue wipes away to reveal normal-appearing pink mucosa underneath, while thrush leaves a raw, erythematous surface. In a breastfed infant with recurrent or persistent thrush, examine the mother for nipple thrush or candidal mastitis and treat both concurrently — miconazole 2% cream to the nipples, with fluconazole added for the mother if her nipples remain symptomatic — since treating only the infant while an untreated maternal reservoir persists is a common, avoidable cause of relapse.[1]
Denture wearers and older adults
See Non-Pharmacologic Management for the full denture-care protocol. Denture stomatitis will not reliably resolve with antifungal treatment alone if the denture itself is not disinfected (or, where genuinely poorly fitting, refit) alongside it — treat the mucosa and the denture as one problem, not two.[2][1]
Diabetes
Glycemic optimization is a genuine adjunct to antifungal treatment, not a separate, unrelated goal — elevated salivary glucose directly feeds Candida overgrowth.[2] Recurrent or unusually severe thrush with no other explanation is also a reasonable prompt to check blood glucose in a patient not already known to have diabetes.
Immunocompromised patients (HIV, transplant, chemotherapy)
Expect a higher relapse rate and consider chronic suppressive fluconazole (100-200 mg three times weekly) for genuinely recurrent disease in this group.[5] For HIV-associated recurrent oropharyngeal or esophageal candidiasis specifically, antiretroviral therapy — not repeated or chronic antifungal courses alone — is the intervention actually shown to reduce recurrence, and is strongly recommended by the IDSA guideline; coordinate ongoing management closely with the treating HIV specialist rather than managing recurrent episodes independently in the pharmacy.[5]
Pregnancy and breastfeeding
Oral azole antifungals are teratogenic and should not be used to treat mucosal candidiasis during the first trimester; topical therapy — clotrimazole troches, nystatin swish-and-swallow, or miconazole — is preferred throughout pregnancy, particularly in the first trimester, with any systemic azole use in later pregnancy individualized with the prescriber.[1] Fluconazole safety data in breastfeeding are reassuring, but any systemic antifungal use during breastfeeding should still be discussed with the prescriber given the range of doses and durations this chapter covers.[1]
Patients using an inhaled corticosteroid for asthma or COPD
See Non-Pharmacologic Management for the complete rinse-and-spit/spacer-technique counseling — the centerpiece prevention conversation of this chapter. Treat any active infection with an appropriate topical or systemic antifungal, reinforce technique at this visit and at every subsequent refill, and never suggest stopping or reducing the inhaled corticosteroid because of thrush; that decision belongs with the prescriber managing the patient's underlying respiratory disease.[4][3]
Children
Beyond infancy, the same topical-first approach applies, with weight-based dosing per the product monograph. Consider the same risk factors as in adults — a recent antibiotic course, an inhaled corticosteroid for pediatric asthma, or, rarely, an underlying immunocompromising condition in a child with recurrent or unexplained disease.
Monitoring & Follow-Up
- Expect improvement within 48-72 hours of starting an appropriate antifungal, and substantial resolution by the end of the minimum 2-week topical course; continue treatment a few days past resolution to reduce the chance of early relapse.[3][2]
- Confirm adherence and correct technique at follow-up — full swish/dissolution time for suspension or troches, and denture removal during any oral rinse.
- For denture wearers: confirm that daily disinfection is actually happening, not just that the patient was told to do it — this is one of the most common, easily overlooked points of failure behind a "recurrent" case that is really an incompletely treated first case.[2]
- For patients on an inhaled corticosteroid: reassess rinse-and-spit habit and, for a metered-dose inhaler, spacer technique at every refill, not just once at the original counseling encounter.[4]
- New or recurrent episodes with no obvious explanation should prompt revisiting Red Flags and Referral rather than simply repeating the same antifungal course again.[1]
- For patients on a prolonged or repeated course of a systemic azole (fluconazole, itraconazole, posaconazole, voriconazole), consider periodic liver function monitoring given the shared hepatotoxicity risk across this drug class.[5]
- Once the infection has cleared, confirm the patient has replaced their toothbrush.[3]
Common Errors to Avoid
- Treating oral thrush in a denture wearer with antifungal medication alone, without addressing denture disinfection or fit — a near-guaranteed path to relapse.[2]
- Assuming any white plaque that does not wipe off is simply a more resistant version of thrush, rather than recognizing hyperplastic candidiasis and its dysplasia/malignancy risk.[1]
- Suggesting a patient stop or reduce their inhaled corticosteroid because of thrush, rather than treating the infection and reinforcing rinse-and-spit/spacer technique — asthma or COPD control takes priority, and thrush is a manageable, treatable side effect.[4]
- Treating inhaled-corticosteroid technique review as a one-time conversation rather than a recurring one — every refill is a genuine opportunity to check technique again.[4]
- Managing recurrent thrush symptomatically, course after course, without ever systematically asking "what changed" — antibiotics, corticosteroids, dentures, diabetes control, or immunocompromise.
- Missing the HIV-testing conversation in a patient with recurrent or severe thrush and no obvious local cause — a genuinely important, easy-to-miss red flag.[1]
- Overlooking drug interactions with systemic azoles — fluconazole, itraconazole, voriconazole, and posaconazole are all significant CYP450 players, and warfarin is a classic example of a drug whose effect can be meaningfully potentiated.
- Combining a nystatin rinse and a chlorhexidine gluconate denture soak or rinse without separating them in time — the two inactivate each other.[1]
- Discontinuing topical treatment as soon as symptoms improve rather than completing the full minimum-2-week course and continuing a few days past resolution — early discontinuation is a common, avoidable cause of relapse.[3]
- Reaching for oral ketoconazole as a systemic option because it appears in some older references — Health Canada restricted its approved indications in 2013 specifically because of hepatotoxicity risk, and it is no longer an appropriate choice for oropharyngeal candidiasis given the availability of fluconazole and the other systemic options in this chapter.[6]
Clinical Decision Algorithm
Drug Tables
How to use this table: systemic antifungal doses require patient-specific confirmation (hepatic function, drug interactions, pregnancy status). Topical antifungal and denture-care product doses are standard adult doses — confirm against the product's own labelling. Drug pricing is intentionally omitted. Select any linked drug name to open its complete Pharmasist Drug Database page.
Topical (Local) Antifungals — First-Line for Mild-to-Moderate Disease
Appropriate for localized oropharyngeal disease without red-flag features — see Choose Initial Treatment.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Nystatin (oral suspension) | Adults: 100,000 units/mL suspension: 4-6 mL, swish for several minutes then swallow, 4 times daily for a minimum of 2 weeks, continued a few days past symptom resolution Infants/children: Weight-based dosing per the product monograph; apply directly to oral lesions | GI upset (nausea, diarrhea), unpleasant taste | Inactivated by, and inactivates, chlorhexidine gluconate if combined — separate the two in time if both are used (for example, for a denture soak) | First-line topical option. High sucrose content in some formulations — caution with diabetes or high caries risk. Remove any denture before rinsing and treat the denture-bearing mucosa directly. |
| Clotrimazole (troches) | Adults: 10 mg troche, dissolved slowly in the mouth, 5 times daily for a minimum of 2 weeks | GI upset, mildly elevated liver enzymes | None significant at standard topical/oral-troche use | Requires 15-20 minutes of dissolution and adequate saliva — less suitable with significant dry mouth. High sucrose content — same diabetes/caries caution as nystatin. |
| Miconazole | Adults: Per the product's own Drug Database monograph Angular cheilitis: Apply to affected corners of the mouth; continue for about 10 days after visible resolution | GI upset if swallowed in quantity, local irritation | A clinically significant CYP3A4/CYP2C9 inhibitor even with buccal or topical use in some formulations — review for interacting medications, particularly warfarin | A reasonable alternative to nystatin/clotrimazole; the topical cream form is specifically useful for angular cheilitis and for applying directly to the internal (tissue-contacting) surface of a denture in denture stomatitis. |
Systemic Antifungals — Moderate-to-Severe, Esophageal, or Refractory Disease
Reserve for disease that does not meet the criteria for topical therapy alone, or that has not responded to an adequate topical course — see Choose Initial Treatment.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Fluconazole | Oropharyngeal disease: 100-200 mg PO once daily for 7-14 days Esophageal disease: 200-400 mg PO once daily for 14-21 days Chronic suppression, recurrent disease: 100-200 mg PO 3 times weekly | GI upset, headache; rare hepatotoxicity; QTc prolongation | One of the most interaction-prone antifungals via CYP450 (warfarin, phenytoin, sulfonylureas, many statins, and others) — review the full medication list carefully before recommending or dispensing | First-line systemic option. A single higher loading dose on day 1 is used by some regimens before dropping to the daily maintenance dose. |
| Itraconazole | Refractory disease: Oral solution, 200 mg once daily, without food, typically for up to 28 days | GI upset, negative inotropic effect (avoid in heart failure), hepatotoxicity | Extensive CYP3A4 interactions; requires an acidic gastric environment for absorption, reduced by acid-suppressing therapy | Fluconazole-refractory disease, specialist-directed. The oral solution — not capsules — is the formulation actually studied for this indication, since absorption differs meaningfully between formulations. |
| Posaconazole | Refractory disease: Suspension 400 mg twice daily for 3 days, then 400 mg once daily, for a total course of up to 28 days | GI upset, QTc prolongation, hepatotoxicity | Extensive CYP3A4 interaction profile | Fluconazole-refractory disease, specialist-directed (infectious diseases or oral medicine) — not a routine pharmacy-initiated step. |
| Voriconazole | Refractory disease: 200 mg twice daily | Visual disturbances, photosensitivity, hepatotoxicity, QTc prolongation | Extensive CYP450 interactions; requires individualized dosing | An alternative to posaconazole for fluconazole-refractory disease, specialist-directed. |
| Amphotericin B (oral suspension) | Refractory disease: 100 mg/mL suspension, swish and swallow, 4 times daily | GI upset; minimal systemic absorption and toxicity with the oral suspension specifically | None significant with the oral suspension, given its minimal systemic absorption | A genuinely different formulation from intravenous amphotericin B — the oral suspension acts topically within the mouth and carries essentially none of IV amphotericin B's systemic toxicity. An option for refractory disease when azole therapy cannot be used. |
Denture Care and Adjunctive Products
Adjuncts to, not substitutes for, an antifungal chosen from the two groups above — see Non-Pharmacologic Management.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Chlorhexidine gluconate 0.12% (denture soak) | Denture soak: Daily, per product labelling | None significant when used as a denture soak rather than an oral rinse | Inactivates, and is inactivated by, nystatin if combined — separate the two in time | Soak the denture daily; rinse thoroughly before reinsertion. |
| Diluted sodium hypochlorite (household bleach, denture soak) | Denture soak: Approximately 1 teaspoon (5 mL) of household bleach per 8 oz (240 mL) of water; rinse the denture thoroughly before reinsertion | Corrosive to metal denture components — confirm the denture has none before using | None significant | An inexpensive, effective alternative to chlorhexidine for an all-acrylic denture with no metal clasps or framework. |
| Hydrocortisone 1% (topical cream) | Angular cheilitis, short course only: Apply sparingly to the affected corners of the mouth; discontinue once inflammation settles | Local skin atrophy with prolonged use | None significant | A brief, adjunctive course alongside — never instead of — a topical antifungal for angular cheilitis with significant inflammation; does not treat the underlying Candida (and, where present, bacterial) component on its own. |
References
- Oral Candidiasis — StatPearls (Taylor M, Brizuela M, Raja A). StatPearls Publishing, updated July 4, 2023
- Managing Patients With Oral Candidiasis — Journal of the Canadian Dental Association (Ng S). J Can Dent Assoc 2013;79:d122
- Oral Candidiasis: What You Need to Know — Canadian Pharmacists Association. CPhA Patient/Pharmacist Infographic
- Breathe Easy: Medications — Asthma Canada. Asthma Canada, Breathe Easy Series, (c) 2016, endorsed by the Family Physician Airways Group of Canada
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America — Infectious Diseases Society of America (Pappas PG, Kauffman CA, Andes DR, et al.). Clin Infect Dis 2016;62(4):e1-e50
- The Rise and Fall of Oral Ketoconazole — Journal of Cutaneous Medicine and Surgery (Gupta AK, Lyons DCA). J Cutan Med Surg 2015;19(4):352-357
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.